Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00750282
Registration number
NCT00750282
Ethics application status
Date submitted
9/09/2008
Date registered
10/09/2008
Date last updated
24/07/2014
Titles & IDs
Public title
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral ß-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
Query!
Scientific title
An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection/Exclusion of Cerebral Amyloid Beta in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
Query!
Secondary ID [1]
0
0
2007-002256-42
Query!
Secondary ID [2]
0
0
311741
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer Disease
0
0
Query!
Amyloid Beta-Protein
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Florbetaben (BAY94-9172)
Experimental: Florbetaben (BAY94-9172) -
Treatment: Drugs: Florbetaben (BAY94-9172)
Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth
Query!
Assessment method [1]
0
0
Part A: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan which was considered a match for specificity. Standard of truth was the onsite clinical diagnosis.
Two Beta-Amyloid Plaque Load (BAPL) algorithms for assessing the normality/abnormality of beta-amyloid plaque load in the brain scans were used.
Using algorithm A (Majority Read), a brain scan of a subject with a BAPL score of "1" (without beta-amyloid plaque load) or "2" (with minor beta-amyloid plaque load) was considered normal and a BAPL score of "3" (with significant beta-amyloid plaque load) was considered abnormal.
Using algorithm B (Average), a brain scan of a subject with a BAPL score of "1" was considered normal and a brain scan with a BAPL score of "2" or "3" was considered abnormal. Algorithm B was used in Part B and in the final
Query!
Timepoint [1]
0
0
90 - 110 min after investigational medical product (IMP) injection
Query!
Primary outcome [2]
0
0
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.
Query!
Assessment method [2]
0
0
Part B: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan, ie,abnormal scan (BAPL scores "2" or "3") which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan, ie,normal scan (BAPL score "1") which was considered a match for specificity.
The clinical diagnosis was established by an independent consensus panel (CP) of experts in dementia.
Two independent sets of PET data reads were performed. The first set was performed by a panel of three readers who received live, instructor-led training on the visual assessment procedure. The second set was performed by a panel of five separate readers who were trained on the visual assessment procedure with electronic media.
Query!
Timepoint [2]
0
0
90 - 110 min after IMP injection
Query!
Secondary outcome [1]
0
0
Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment
Query!
Assessment method [1]
0
0
PET scans from two additional imaging windows (45-60 min and 110-130 min) were visually assessed
Query!
Timepoint [1]
0
0
45 - 60 min and 110 - 130 min after IMP injection
Query!
Secondary outcome [2]
0
0
Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)
Query!
Assessment method [2]
0
0
The agreement between 3 blinded readers concerning the visual assessment of abnormality of the brain scan (based on BAPL score) was measured by the kappa coefficient. Kappa values close to 1.0 indicate a high agreement while values close to 0 indicate random agreement.
Query!
Timepoint [2]
0
0
45-60 min, 90-110 min, 110-130 min
Query!
Secondary outcome [3]
0
0
Standard Uptake Value Ratios for Florbetaben Signal
Query!
Assessment method [3]
0
0
The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, lateral temporal cortex, parietal cortex, anterior cingulate, posterior cingulate cortex, occipital cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.)
Query!
Timepoint [3]
0
0
90-110 min post injection
Query!
Eligibility
Key inclusion criteria
* Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study:
* Is a man or woman and is > 55 of age, whereby females must be without childbearing potential (confirmed by either: age >/= 60; or history of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start)
* Has at least 6 years of education
* Is able to provide informed consent, understand the information provided on the purpose and conduct of the trial and to comply with study procedures
* Possesses a general health that permits adequate compliance with all study procedures
* The subject, or the subject and caregiver (for probable AD patients) will be compliant and have a high probability of completing the study
* Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable AD patients)
* Inclusion criteria for HV only:
* Has no evidence of cognitive impairment
* Has MRI brain scan that has been judged as "normal" (age- appropriate)
* Inclusion criteria for patients with AD only:
* Presents with positive assessment for dementia of Alzheimer's type
* Does not fulfill the criteria Dementia with Lewy Bodies (DLB) or Vascular Dementia (VaD)
* MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease
* Has a caregiver that is willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver
Query!
Minimum age
55
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has any contraindication to MRI examination scan
* Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application
* Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma)
* is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable
* Has a history of exposure to any radiation >15 milli Sieverts (mSv)/year (e.g. occupational or radiation therapy)
* Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)
* Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical
* Has a brain tumor or other intracranial lesion, a disturbance of cerebro-spinal fluid (CSF) circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery
* Has an inflammatory or infectious central nervous system (CNS) disease, e.g. multiple sclerosis, HIV, syphilis, or Creutzfeldt-Jacob disease
* Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness
* Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function)
* Has a history of alcohol or drug abuse
* Has history of severe persistent depression
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
422
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
- Westmead
Query!
Recruitment hospital [2]
0
0
- Adelaide
Query!
Recruitment hospital [3]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Rhode Island
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Bayern
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Nordrhein-Westfalen
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Sachsen
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Berlin
Query!
Country [10]
0
0
Japan
Query!
State/province [10]
0
0
Hyogo
Query!
Country [11]
0
0
Japan
Query!
State/province [11]
0
0
Tokyo
Query!
Country [12]
0
0
Switzerland
Query!
State/province [12]
0
0
Zürich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Life Molecular Imaging SA
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission tomography (PET). IMP binds to amyloidal beta protein accumulating in brain tissue already from early stages of Alzheimer's disease (AD). IMP is therefore a potential tracer to be used for detecting amyloid plaques. For each subject it is required to visit the study centre during the screening phase, on the PET imaging day and for 1 follow-up visit on the next day. A telephone call for safety follow-up will be performed 7 days after IMP administration. During the screening phase the subject's medical, neurological and surgical history, specific laboratory tests related to AD, MRI of the brain and certain neuro-psychiatric tests will be performed. Clinical safety measures (physical examinations, vital signs, electrocardiogram (ECG) and laboratory tests) will be performed on the PET imaging day before IMP injection and monitored during and after two PET imaging sessions. Clinical safety measures will be performed again on the follow-up visit next day. The results of PET imaging with IMP will be compared between probable AD patients and healthy volunteers (HV). The clinical diagnosis is based on international validated and accepted criteria and established after comprehensive clinical and neuro-psychiatric examinations
Query!
Trial website
https://clinicaltrials.gov/study/NCT00750282
Query!
Trial related presentations / publications
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8. Bullich S, Roe-Vellve N, Marquie M, Landau SM, Barthel H, Villemagne VL, Sanabria A, Tartari JP, Sotolongo-Grau O, Dore V, Koglin N, Muller A, Perrotin A, Jovalekic A, De Santi S, Tarraga L, Stephens AW, Rowe CC, Sabri O, Seibyl JP, Boada M. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021 Mar 27;13(1):67. doi: 10.1186/s13195-021-00807-6.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenste...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00750282
Download to PDF